Skip to content
Screener

Praxis Precision Medicines, Inc. PRAX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$11.86B+2.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.3B+92.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$443.28M+8.9%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$458.98M+60.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$3.5M
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$4.91B+33.0%

Other financials

Income statement

See full
Revenue--100%
Operating income-$96.9M-27.4%
Net income-$83.7M-17.7%
EPS (diluted)-$2.87+13.3%

Balance sheet

See full
Cash & equivalents$474.8M+201%
Total debt$1.1M+44.0%
Total equity$1.3B+232%
Total assets$1.4B+207%

Cash flow

See full
Operating cash flow-$77.5M-41.8%
CapEx$245.0K+338%
Free cash flow-$77.8M-42.1%

Valuation

See full
Market cap$8.9B+770%
Enterprise value$8.43B+873%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-38.9%-10.3pp
Debt / equity0.0×
Current ratio15.7×+9.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:32 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001689548-26-000083
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.0001 par value; 150,000,000 shares authorized; 27,916,593 shares issued and outstanding as of June 30, 2026, and 25,195,092 shares issued and outstanding as of December 31, 20251515
Additional paid-in capital2,659,9902,017,566
Accumulated deficit(1,316,289)(1,140,008)
Accumulated other comprehensive (loss) gain(2,672)563
Total stockholders’ equity1,341,044878,136
Total liabilities and stockholders’ equity$1,390,102$937,907

Item 1. Financial Statements (Unaudited)

FAQ

What is Praxis Precision Medicines, Inc.'s total liabilities & equity?
Praxis Precision Medicines, Inc. (PRAX) reported total liabilities & equity of $1.39B in Q2 2026.
How has Praxis Precision Medicines, Inc.'s total liabilities & equity changed year-over-year?
Praxis Precision Medicines, Inc.'s total liabilities & equity increased by 207.0% year-over-year, from $452.83M to $1.39B.
What is the long-term trend for Praxis Precision Medicines, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s total liabilities & equity has grown at a 25.3% compound annual growth rate (CAGR), from $303.18M to $937.91M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Praxis Precision Medicines, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude